Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. OncoSil Medical's net income from continuing operations for the
six
months ended in Dec. 2025 was A$-4.53 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-12.92 Mil.
OncoSil Medical Net Income From Continuing Operations Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's Net Income From Continuing Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSil Medical Net Income From Continuing Operations Chart
OncoSil Medical Net Income From Continuing Operations Calculation
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-12.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income From Continuing Operations of A$-12.92 Mil mean?
OncoSil Medical (ASX:OSL) has a Net Income From Continuing Operations of A$-12.92 Mil as of Dec. 2025. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for OncoSil Medical and its competitors.
Is OncoSil Medical's Net Income From Continuing Operations too high?
OncoSil Medical's current Net Income From Continuing Operations is A$-12.92 Mil. Overall, OncoSil Medical has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Net Income From Continuing Operations compare to ABT and SYK?
OncoSil Medical's Net Income From Continuing Operations of A$-12.92 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Medical Devices & Instruments company?
A good Net Income From Continuing Operations depends on the Medical Devices & Instruments industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for OncoSil Medical and its competitors. OncoSil Medical's current Net Income From Continuing Operations is A$-12.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.92, compared to a current price of A$1.20 — trading 58.9% below its estimated fair value. The current Net Income From Continuing Operations is A$-12.92 Mil. OncoSil Medical's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Net Income From Continuing Operations is A$-12.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.20 is trading 58.9% below its estimated GF Value™ of A$2.92.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Net Income From Continuing Operations: A$-12.92 Mil
GF Value™: A$2.92 vs. price of A$1.20 (58.9% below fair value)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
40GF Score
Get the complete analysis for ASX:OSL
Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
